文献速递膀胱癌与上尿路尿路上皮癌

复发性非肌层浸润性膀胱癌随访中可疑膀胱镜检查患者的尿液标志物表现:BTA Stat、NMP22 BladderChek、UBC快速检测、CancerCheck UBC快速可视化检测和Uromonitor与细胞学的比较

Performance of Urinary Markers in Patients With Suspicious Cystoscopy During Follow-up of Recurrent Non-muscle Invasive Bladder Cancer: BTA Stat, NMP22 BladderChek, UBC Rapid Test, CancerCheck UBC Rapid VISUAL, and Uromonitor in Comparison to Cytology.
PubMed 文献 · Urology · 2024-12-01

这项多中心研究分析了187例复发性非肌层浸润性尿路上皮膀胱癌随访中膀胱镜检查可疑患者的尿液样本,其中110例切除标本显示复发性尿路上皮癌。比较BTA stat、NMP22 BladderChek、UBC快速检测、CancerCheck UBC快速可视化检测、Uromonitor和细胞学的灵敏度和特异度,发现多数尿液标志物灵敏度高于细胞学,BTA stat、UBC快速检测和Uromonitor在此场景下似乎有用。

要点

  • 在复发性非肌层浸润性膀胱癌随访中,多数尿液标志物检测复发性膀胱癌的灵敏度和特异度高于细胞学。
  • 低级别非肌层浸润性膀胱癌中,BTA stat灵敏度60.0%、Uromonitor 54.5%、UBC快速检测58.0%,均高于细胞学41.5%。
  • 高级别非肌层浸润性膀胱癌中,UBC快速检测灵敏度77.8%、细胞学65.5%、BTA stat 64.0%、Uromonitor 56.0%。

核心结论

  • 在随访期间,多数尿液标志物检测复发性膀胱癌的灵敏度和特异度高于细胞学。
  • BTA stat、UBC快速检测和Uromonitor在此场景下似乎有用。

研究设计与样本

  • 多中心研究,分析187例复发性非肌层浸润性尿路上皮膀胱癌随访中膀胱镜检查可疑患者的尿液样本。
  • 所有可疑病灶均予切除,其中110例样本显示复发性尿路上皮癌。
  • 尿液样本采用BTA stat、NMP22 BladderChek、UBC快速检测、CancerCheck UBC快速可视化检测、Uromonitor和细胞学分析,通过列联表分析计算灵敏度和特异度。

主要发现

  • 所有研究的尿液标志物在膀胱癌患者尿液中检测到病理结果的比例均高于无肿瘤患者尿液。
  • 非肌层浸润性低级别膀胱癌中,BTA stat、NMP22 BladderChek、UBC快速检测、CancerCheck UBC快速可视化检测、Uromonitor和细胞学的灵敏度分别为60.0%、10.0%、58.0%、32.0%、54.5%和41.5%。
  • 非肌层浸润性高级别膀胱癌中,上述标志物的灵敏度分别为64.0%、40.0%、77.8%、50.0%、56.0%和65.5%。
  • BTA stat、NMP22 BladderChek、UBC快速检测、CancerCheck UBC快速可视化检测、Uromonitor和细胞学的特异度分别为51.3%、94.8%、66.2%、89.5%、94.9%和66.2%。

临床怎么用

  • 原文结论认为BTA stat、UBC快速检测和Uromonitor在复发性非肌层浸润性膀胱癌随访中似乎有用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare all available rapid tests on a large cohort of recurrent bladder cancer during follow-up in this multicentre-study is the first study. BTA stat, NMP22 BladderChek, UBC Rapid Test CancerCheck UBC rapid VISUAL, and uromonitor are urinary-based rapid tests for bladder cancer detection. METHODS: In total, 187 urine samples were analyzed from patients with suspected recurrent non-muscle invasive urothelial bladder cancer on cystoscopy during follow-up in a real-world assessment. All suspicious lesions were resected with 110 samples showing recurrent urothelial cancer. Urine samples were analyzed by the BTA stat, NMP22 BladderChek, UBC Rapid Test, CancerCheck UBC rapid VISUAL, uromonitor, and cytology. Sensitivities and specificities were calculated by contingency analyses. RESULTS: All investigated urinary markers could detect a higher percentage of pathological results in urine of bladder cancer patients compared to urine of tumor free patients. The calculated diagnostic sensitivities for BTA stat, NMP22 BladderChek, UBC Rapid Test, CancerCheck UBC rapid VISUAL, uromonitor, and cytology were 60.0%, 10.0%, 58.0%, 32.0%, 54.5%, and 41.5% for non-muscle invasive low-grade, and 64.0%, 40.0%, 77.8%, 50.0%, 56.0%, and 65.5% for non-muscle invasive high-grade bladder cancer. The specificity was 51.3%, 94.8%, 66.2%, 89.5%, 94.9%, and 66.2%, respectively. CONCLUSION: During follow-up sensitivities and specificities of most urinary markers are higher compared to cytology for the detection of recurrent bladder cancer. BTA stat, UBC Rapid Test, and uromonitor appear useful in this setting.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Ecke TH, Meisl CJ, Schlomm T, et al. Performance of Urinary Markers in Patients With Suspicious Cystoscopy During Follow-up of Recurrent Non-muscle Invasive Bladder Cancer: BTA Stat, NMP22 BladderChek, UBC Rapid Test, CancerCheck UBC Rapid VISUAL, and Uromonitor in Comparison to Cytology. Urology. 2024. PMID: 39626834. doi:10.1016/j.urology.2024.11.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。